GLP-1s Are Being Linked to Fewer Serious Infections, Including TB
Recent research shows that GLP‑1 receptor agonists, used for diabetes and weight control, may lower the risk of serious infections such as tuberculosis. The study compared infection rates between patients on GLP‑1 therapy and those not receiving it, finding a statistically significant reduction in severe infections among the GLP‑1 group. These results could affect prescribing for high‑risk patients.